The lack of data regarding the PD-L1 status for 21% of the patients could be contributed to the fact that they were diagnosed with advanced NSCLC prior to the introduction of first-line pembrolizumab therapy for the PD-L1 > 50% subset of patients, and thus, PD-L1 status was not routinely tested for. Here, CD274 is linked to non-small cell lung carcinoma.